Use of mesenchymal stem cells for therapy of cardiac disease

Vasileios Karantalis, Joshua M. Hare

Research output: Contribution to journalArticle

Abstract

Despite substantial clinical advances over the past 65 years, cardiovascular disease remains the leading cause of death in America. The past 15 years has witnessed major basic and translational interest in the use of stem and precursor cells as a therapeutic agent for chronically injured organs. Among the cell types under investigation, adult mesenchymal stem cells are widely studied, and in early stage, clinical studies show promise for repair and regeneration of cardiac tissues. The ability of mesenchymal stem cells to differentiate into mesoderm-and nonmesoderm-derived tissues, their immunomodulatory effects, their availability, and their key role in maintaining and replenishing endogenous stem cell niches have rendered them one of the most heavily investigated and clinically tested type of stem cell. Accumulating data from preclinical and early phase clinical trials document their safety when delivered as either autologous or allogeneic forms in a range of cardiovascular diseases, but also importantly define parameters of clinical efficacy that justify further investigation in larger clinical trials. Here, we review the biology of mesenchymal stem cells, their interaction with endogenous molecular and cellular pathways, and their modulation of immune responses. Additionally, we discuss factors that enhance their proliferative and regenerative ability and factors that may hinder their effectiveness in the clinical setting.

Original languageEnglish (US)
Pages (from-to)1413-1430
Number of pages18
JournalCirculation Research
Volume116
Issue number8
DOIs
StatePublished - Apr 10 2015
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Heart Diseases
Cardiovascular Diseases
Stem Cells
Clinical Trials
Stem Cell Niche
Adult Stem Cells
Mesoderm
Cell Communication
Regeneration
Cause of Death
Safety
Therapeutics

Keywords

  • Cell differentiation
  • Mesenchymal stem cell
  • Regeneration
  • Stem cells

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Use of mesenchymal stem cells for therapy of cardiac disease. / Karantalis, Vasileios; Hare, Joshua M.

In: Circulation Research, Vol. 116, No. 8, 10.04.2015, p. 1413-1430.

Research output: Contribution to journalArticle

Karantalis, Vasileios ; Hare, Joshua M. / Use of mesenchymal stem cells for therapy of cardiac disease. In: Circulation Research. 2015 ; Vol. 116, No. 8. pp. 1413-1430.
@article{993755bba9294c439afa19994570b719,
title = "Use of mesenchymal stem cells for therapy of cardiac disease",
abstract = "Despite substantial clinical advances over the past 65 years, cardiovascular disease remains the leading cause of death in America. The past 15 years has witnessed major basic and translational interest in the use of stem and precursor cells as a therapeutic agent for chronically injured organs. Among the cell types under investigation, adult mesenchymal stem cells are widely studied, and in early stage, clinical studies show promise for repair and regeneration of cardiac tissues. The ability of mesenchymal stem cells to differentiate into mesoderm-and nonmesoderm-derived tissues, their immunomodulatory effects, their availability, and their key role in maintaining and replenishing endogenous stem cell niches have rendered them one of the most heavily investigated and clinically tested type of stem cell. Accumulating data from preclinical and early phase clinical trials document their safety when delivered as either autologous or allogeneic forms in a range of cardiovascular diseases, but also importantly define parameters of clinical efficacy that justify further investigation in larger clinical trials. Here, we review the biology of mesenchymal stem cells, their interaction with endogenous molecular and cellular pathways, and their modulation of immune responses. Additionally, we discuss factors that enhance their proliferative and regenerative ability and factors that may hinder their effectiveness in the clinical setting.",
keywords = "Cell differentiation, Mesenchymal stem cell, Regeneration, Stem cells",
author = "Vasileios Karantalis and Hare, {Joshua M.}",
year = "2015",
month = "4",
day = "10",
doi = "10.1161/CIRCRESAHA.116.303614",
language = "English (US)",
volume = "116",
pages = "1413--1430",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Use of mesenchymal stem cells for therapy of cardiac disease

AU - Karantalis, Vasileios

AU - Hare, Joshua M.

PY - 2015/4/10

Y1 - 2015/4/10

N2 - Despite substantial clinical advances over the past 65 years, cardiovascular disease remains the leading cause of death in America. The past 15 years has witnessed major basic and translational interest in the use of stem and precursor cells as a therapeutic agent for chronically injured organs. Among the cell types under investigation, adult mesenchymal stem cells are widely studied, and in early stage, clinical studies show promise for repair and regeneration of cardiac tissues. The ability of mesenchymal stem cells to differentiate into mesoderm-and nonmesoderm-derived tissues, their immunomodulatory effects, their availability, and their key role in maintaining and replenishing endogenous stem cell niches have rendered them one of the most heavily investigated and clinically tested type of stem cell. Accumulating data from preclinical and early phase clinical trials document their safety when delivered as either autologous or allogeneic forms in a range of cardiovascular diseases, but also importantly define parameters of clinical efficacy that justify further investigation in larger clinical trials. Here, we review the biology of mesenchymal stem cells, their interaction with endogenous molecular and cellular pathways, and their modulation of immune responses. Additionally, we discuss factors that enhance their proliferative and regenerative ability and factors that may hinder their effectiveness in the clinical setting.

AB - Despite substantial clinical advances over the past 65 years, cardiovascular disease remains the leading cause of death in America. The past 15 years has witnessed major basic and translational interest in the use of stem and precursor cells as a therapeutic agent for chronically injured organs. Among the cell types under investigation, adult mesenchymal stem cells are widely studied, and in early stage, clinical studies show promise for repair and regeneration of cardiac tissues. The ability of mesenchymal stem cells to differentiate into mesoderm-and nonmesoderm-derived tissues, their immunomodulatory effects, their availability, and their key role in maintaining and replenishing endogenous stem cell niches have rendered them one of the most heavily investigated and clinically tested type of stem cell. Accumulating data from preclinical and early phase clinical trials document their safety when delivered as either autologous or allogeneic forms in a range of cardiovascular diseases, but also importantly define parameters of clinical efficacy that justify further investigation in larger clinical trials. Here, we review the biology of mesenchymal stem cells, their interaction with endogenous molecular and cellular pathways, and their modulation of immune responses. Additionally, we discuss factors that enhance their proliferative and regenerative ability and factors that may hinder their effectiveness in the clinical setting.

KW - Cell differentiation

KW - Mesenchymal stem cell

KW - Regeneration

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84936979255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936979255&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.116.303614

DO - 10.1161/CIRCRESAHA.116.303614

M3 - Article

C2 - 25858066

AN - SCOPUS:84936979255

VL - 116

SP - 1413

EP - 1430

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 8

ER -